title: Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency.
authors.affiliation: Baylor Research Institute, Dallas, Texas, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Gibson
authors.forename: C
authors.initials: C
authors.lastname: Jakobs
authors.forename: H
authors.initials: H
authors.lastname: Ogier
authors.forename: L
authors.initials: L
authors.lastname: Hagenfeldt
authors.forename: K E
authors.initials: KE
authors.lastname: Eeg-Olofsson
authors.forename: O
authors.initials: O
authors.lastname: Eeg-Olofsson
authors.forename: F
authors.initials: F
authors.lastname: Aksu
authors.forename: H P
authors.initials: HP
authors.lastname: Weber
authors.forename: E
authors.initials: E
authors.lastname: Rossier
authors.forename: B
authors.initials: B
authors.lastname: Vollmer
mesh_terms: D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000445:Aldehyde Oxidoreductases / Q000172:deficiency*; D001928:Brain Diseases, Metabolic / Q000150:complications / Q000188:drug therapy; D018756:GABA Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000150:complications / Q000188:drug therapy*; D012640:Seizures / Q000139:chemically induced; D012978:Sodium Oxybate / Q000134:cerebrospinal fluid; D050644:Succinate-Semialdehyde Dehydrogenase; D016896:Treatment Outcome; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000627:therapeutic use
chemical_list: D018756:GABA Antagonists; D005680:gamma-Aminobutyric Acid; D012978:Sodium Oxybate; D000445:Aldehyde Oxidoreductases; C493643:ALDH5A1 protein, human; D050644:Succinate-Semialdehyde Dehydrogenase; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin